Jerry C. Griffin - Jul 31, 2023 Form 4 Insider Report for Inspire Medical Systems, Inc. (INSP)

Role
Director
Signature
/s/ Bryan Phillips, as Attorney-in-Fact for Jerry C. Griffin
Stock symbol
INSP
Transactions as of
Jul 31, 2023
Transactions value $
-$137,659
Form type
4
Date filed
8/1/2023, 06:26 PM
Previous filing
Jul 26, 2023
Next filing
Mar 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSP Common Stock Options Exercise $16K +1K +11.93% $16.00 9.38K Jul 31, 2023 Direct
transaction INSP Common Stock Sale -$8.42K -29 -0.31% $290.47 9.35K Jul 31, 2023 Direct F1
transaction INSP Common Stock Sale -$145K -500 -5.35% $290.47 8.85K Jul 31, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INSP Stock Option (Right to Buy) Options Exercise $0 -1K -18.88% $0.00 4.3K Jul 31, 2023 Common Stock 1K $16.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reflects shares sold to cover taxes upon the option exercise pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 15, 2023 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3 The option is fully vested and exercisable.